Articles related to ANTITHROMBOTIC THERAPY

The study underscores the potential of dual antiplatelet therapy in reducing the risk of recurrent stroke. However, it also highlights the need for careful patient selection due to the slightly increased risk of moderate-to-severe bleeding.

Explore the complex interplay between MTHFR gene variants and thrombosis risk. This deep dive into the latest research reveals surprising insights.

The study’s findings suggest a potential paradigm shift in the management of cancer patients with isolated distal DVT. With the 12-month edoxaban regimen reducing the occurrence of the primary composite endpoint to just 1.0% compared to 7.2% in the three-month group, this could represent a significant advancement in patient care.

Recent studies and guidelines are shifting the paradigm in coagulation management for cirrhosis patients undergoing low-risk procedures; discover why traditional markers like INR may not be reliable indicators of bleeding risk.

Dive into this intriguing case of a young woman presenting with right calf pain and an acute thrombosis. Join your peers in discerning the most appropriate therapeutic strategy, deepening your clinical acumen in the process.

The new recommendations include continuing antiplatelet therapy for patients with a baseline indication for it, starting dual antiplatelet therapy for patients with confirmed ACS, and adding prophylactic-dose LMWH for patients on antiplatelet therapy for a previous stroke.